3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
121
Melanoma
111
Neoplasms
66
Carcinoma, Renal Cell
60
Colorectal Neoplasms
43
Neoplasm Metastasis
39
Squamous Cell Carcinoma of Head and Neck
36
Stomach Neoplasms
35
Carcinoma, Hepatocellular
33
Carcinoma, Transitional Cell
27
Lung Neoplasms
23
Pancreatic Neoplasms
22
Triple Negative Breast Neoplasms
21
Ovarian Neoplasms
21
Head and Neck Neoplasms
21
Advanced Cancer
19
Breast Neoplasms
17
Urinary Bladder Neoplasms
15
Small Cell Lung Carcinoma
14
Kidney Neoplasms
13
Recurrence
11
Hodgkin Disease
11
Uterine Cervical Neoplasms
10
Skin Neoplasms
10
Lymphoma
10
Solid Tumor
9
Mesothelioma
9
Endometrial Neoplasms
9
Carcinoma, Merkel Cell
9
Carcinoma
9
Interventions
sargramostim
2
Monatide (IMS 3015)
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Azacitidine
2
venetoclax
1
ruxolitinib
1
rucaparib
1
olaparib
1
cc-486
1
Pemetrexed
1
Observation
1
Nivolumab
1
Decitabine
1
Cytarabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pathologic Complete Response
×
Nivolumab
×
Clear all
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts